CVS Health announced that its drug plans will include the over-the-counter birth control pill, Opill, at no cost for many health plan sponsors. This move is expected to increase access to contraception, particularly for younger women and those in rural and underserved communities. Opill, approved by the FDA, is now available in pharmacies, marking a significant step in expanding contraceptive availability without a prescription.
Key Findings
CVS Health's pharmacy benefit manager, CVS Caremark, will add Opill to its preventive services oral contraceptives list, covering it at zero cost for many sponsors.
Opill, produced by Perrigo, became available in pharmacies from April 1, with a retail price of $19.99 for a one-month supply and $49.99 for a three-month supply.
The FDA's approval of Opill represents the first instance of an over-the-counter birth control pill in the U.S., aiming to enhance contraceptive access.
Big Picture
The introduction and coverage of Opill are part of a larger movement towards improving reproductive rights and access to healthcare in the U.S. This development is aligned with efforts by the Biden administration to bolster reproductive rights amidst rising abortion restrictions.
Ethical Considerations
The decision to make birth control more accessible over the counter presents ethical considerations, including the balance between accessibility and ensuring informed use of contraception. Healthcare providers play a crucial role in educating patients about their options and the proper use of over-the-counter contraceptives.